200 results about "Tumor target" patented technology

The present invention relates to combination therapies employing tumor targeted anti-CEA / CD3 bispecific antibodies and / or agents blocking PD-L1 / PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules that also target FAP, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention discloses iron oxide nanoparticles capable of responding to particle size change in a tumor microenvironment and a preparation method of the iron oxide nanoparticles, and belongs to the technical field of biomedical nano materials. The nano-particle comprises an iron oxide nano-crystal core with the particle size of 3-5nm and a tumor microenvironment response layer coating the surface of the iron oxide nano-crystal core. The response layer contains groups, such as disulfide bonds, enzyme digestion peptide fragments and the like, which can respond to acidic pH, high-concentration reduced glutathione or matrix metalloproteinase and other tumor characteristic stimuli to generate structural changes. In a tumor microenvironment, the hydration particle size of the nanoparticles can be directionally and controllably converted from 3-20 nm to 20-100 nm (or reversely). The preparation method mainly comprises two steps of preparing the core by a thermal decomposition method and modifying the surface response layer. The technical problems of insufficient tumor targeted enrichment capacity, limited imaging contrast and difficulty in balancing permeation and retention caused by fixed particle size of the existing iron oxide nanoparticles are solved, and the accuracy and efficiency of tumor diagnosis and treatment can be remarkably improved.

The invention belongs to the technical field of biomedical functional dyes and probes, and relates to a fluorescent probe, in particular to a cyclodextrin-based near-infrared fluorescent probe, which is a conjugate formed by coating a fluorescent molecule with cyclodextrin. According to the near-infrared fluorescent probe disclosed by the invention, cyclodextrin is nested on a carbon chain of a fluorescent molecule, so that the water solubility, histocompatibility and safety are improved, the fluorescence lifetime is prolonged, the light stability is improved, and rapid transmission and response of ureters, lymphatic vessels and lymph nodes in vivo are realized; the method can be used for NIR-I and NIR-II imaging; a near-infrared fluorescence probe with targeting property can be formed by marking various tumor targeting molecules, so that accurate targeting fluorescence imaging of different types of tumors such as urogenital tumors, head and neck cancers, breast cancers and cervical cancers and metastatic lymph nodes in NIR-I and NIR-II windows is realized, and the near-infrared fluorescence probe can be applied to fluorescence imaging navigation in clinical operations.

The invention relates to the technical field of novel biological nanomaterials, in particular to a lung-targeted exosome complex as well as a preparation method and application thereof. The lung targeting type exosome complex is prepared from an NK cell exosome, lipid nanoparticles and an entrapped anti-tumor nucleic acid drug, the NK cell exosome is obtained by extracting a natural killer cell NK-92MI of a human malignant non-Hodgkin lymphoma patient through a differential centrifugation method. The anti-tumor nucleic acid drug is a specific nucleic acid drug targeting a key canceration driving gene in non-small cell lung cancer. The lung targeting type exosome complex prepared by the invention is an excellent and stable drug delivery carrier, has a good lung tissue targeting function, enhances the tumor targeting effect of the exosome, also exerts the tumor cell killing function of the exosome, and has important significance for the treatment of non-small cell lung cancer.

The invention discloses an aptamer-modified lipid nano delivery platform as well as a preparation method and application thereof, and belongs to the field of biomedicine. The platform is prepared by taking DPPC, DOTAP and cholesterol as basic lipid components, Ce6 as a sound-sensitive agent and Flt3L as an immune agonist, controlling the particle size through gradient extrusion, and coupling cholesterol with an EpCAM aptamer for surface modification. The method has the core advantages that active targeting enrichment of tumors is realized by virtue of the aptamer, tumor cell immunogen cell death (ICD) is induced in combination with a sonodynamic therapy (SDT), and damage-related molecular patterns (DAMPs) are released; meanwhile, Flt3L is released in a tumor microenvironment, collection and activation of type 1 classical dendritic cells (cDC1) are specifically promoted, an'endogenous cDC1 vaccine 'is constructed, and CD8 + T cell mediated anti-tumor immune response is enhanced. Experiments prove that the platform can significantly improve the cDC1 infiltration level of a tumor site, effectively inhibit the progress of prostate cancer (PCa), and provide a new normal form for immune'cold tumor 'treatment.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The invention relates to a bone tumor ablation target region identification and real-time updating method. The method comprises the following steps: processing a multi-modal medical image acquired before an operation, performing information trust empowerment on a bone tumor area according to an image source type, structural definition, bone tissue shielding degree and spatial distribution complexity, and dividing the bone tumor area into a core target area, a semi-trusted marginal area and a dispute area; in the intraoperative ablation process, an ablation temperature change path, power response distribution and navigation position information are continuously monitored, and when it is detected that temperature response is sparse, a needle tip is static and energy motivates discontinuous feature combination in a semi-credible marginal area or a dispute area, target area offset warning logic is triggered; according to the bone tumor target region identification mechanism based on the multi-modal medical image trust empowerment, multi-dimensional information factors such as the image source type, the structure definition, the bone tissue shielding degree and the spatial distribution complexity can be considered at the same time.

The invention relates to the technical field of radiotherapy, and discloses a multi-modal image fusion guided chest tumor adaptive radiotherapy system. The system comprises an asynchronous bimodal sensing module, a spectrum preprocessing module, a parameter inversion module, a boundary construction module and a biomechanical calculation module. According to the method, the feedback voxel-level velocity field is utilized to execute Lagrange reverse warping on the high-energy projection with physical time delay, and motion artifacts are eliminated; and dynamically updating the Young modulus of the lung tissue mechanical model based on the inverted real-time electron density, and solving a full-field three-dimensional displacement field in combination with double boundary conditions of body surface flexibility and internal skeleton rigidity so as to reconstruct a tumor target region and generate a beam control instruction. According to the method, through closed-loop interaction of image physics and biomechanics, the problems of dual-energy imaging motion artifact interference and insufficient lung tissue fixed parameter modeling precision are solved, and accurate self-adaptive tracking of a tumor target region is realized.

The present application relates to the field of immunology, and particularly relates to a novel IL-15 fusion protein and application thereof. The present application provides an IL-15 transmembrane fusion protein, which is applied to NK cells or CAR-NK cells, can significantly enhance the tumor killing function of NK cells and CAR-NK cells, and can effectively promote the proliferation of NK cells and CAR-NK cells. It provides an important basis for developing NK cell products armored by the IL-15 transmembrane fusion protein, which are independent of any tumor target, thereby reducing the cycle and cost of CAR-NK development. Meanwhile, the present application respectively carries out function research in blood tumors expressing CD19 and solid tumors expressing CD276, and the results indicate the broad-spectrum application prospect of the structure in tumors.

The invention discloses an interactive lattice radiotherapy planning method and system based on a functional image, and relates to the technical field of radiotherapy, and the method comprises the steps: obtaining a radiotherapy positioning CT image of a patient and a functional metabolism image after the space registration with the radiotherapy positioning CT image; based on the radiotherapy positioning CT image and a preset safety boundary parameter, determining a candidate area of lattice layout in the tumor target area; for each candidate position in the candidate region, adaptively calculating lattice parameters for the position based on the corresponding SUV value of the position in the functional metabolism image; determining a final lattice center set from the candidate positions through an iterative screening algorithm on the basis of the calculated lattice parameters of the candidate positions and preset geometric constraints and biological constraints, and generating a lattice target region set on the basis of the final lattice centers and the lattice diameters corresponding to the final lattice centers; and outputting the lattice target region set for dose calculation of a radiotherapy planning system. Individualized dosage improvement really based on tumor internal heterogeneity is achieved.

The invention provides a magnetic resonance guided charged particle beam radiotherapy device and an electromagnetic navigation parameter debugging method for target coordinates, and belongs to the technical field of radiotherapy devices. The system comprises a charged particle beam electromagnetic navigation device which comprises multiple stages of electromagnetic navigation coils, charged particle beams sequentially pass through the multiple stages of electromagnetic navigation coils, and parallel charged particle beams consistent with a magnetic resonance main magnetic field in direction are generated; the MR imaging device comprises an MR main magnetic field coil upper group and an MR main magnetic field coil lower group, and an imaging treatment area is formed between the MR main magnetic field coil upper group and the MR main magnetic field coil lower group. The electromagnetic navigation parameter debugging method comprises the steps of constructing a target cost function, optimizing electromagnetic navigation parameters based on an optimization algorithm without gradient information, and determining and outputting optimal navigation parameters. According to the invention, the charged particle beam parallel to the MR main magnetic field can be generated, the influence of Lorentz force on the charged particle beam is greatly reduced, the difficulty of positioning a tumor target region by the charged particle beam under the guidance of MR can be reduced, and the treatment accuracy is improved.

The invention relates to the technical field of tumor molecular imaging, nuclear medicine diagnosis and targeted therapy, and discloses a Trop2-targeted polypeptide, a Trop2-targeted molecular probe and application of the Trop2-targeted polypeptide and the Trop2-targeted molecular probe. The polypeptide can be coupled with different imaging elements to construct molecular probes or radiopharmaceuticals for tumor targeted imaging, so that noninvasive visual detection on the Trop2 expression level in tumor tissues is realized. The probe can specifically recognize Trop2 positive solid tumors, and a new technical means is provided for noninvasive diagnosis and dynamic monitoring of various Trop2 high-expression tumors such as pancreatic cancer, lung cancer, breast cancer and thyroid cancer. The probe disclosed by the invention has the advantages of simple preparation process, low cost, high specificity and stability, short imaging period, low radiation dosage, easiness in clinical transformation and the like, and has a wide application prospect in precise diagnosis and individualized treatment of tumors.

Relates to a lipid composition with targeting property, the lipid composition comprises an active component, a lipid carrier and a targeting component, and the components of the lipid carrier comprise a positively charged component and phospholipid. An active component is entrapped in a lipid carrier containing a component with positive charges, so that the surface of the lipid carrier has positive charges, then the lipid carrier and a targeting component with negative charges are mixed, and the targeting component is adsorbed on the surface of the drug-loaded lipid carrier with positive charges through an electrostatic adsorption effect, so that the drug-loaded lipid carrier which is high in transfection efficiency and good in transfection effect is prepared. The present invention relates to a lipid composition having a targeting property and a high targeting property. The invention relates to a lipid nanoparticle delivery system with high biological activity, tumor targeting property and good safety. The lipid nanoparticle delivery system comprises an active component, cationic lipid, ionizable lipid and neutral phospholipid. The active component is entrapped in the lipid nanoparticle containing the cationic lipid, the ionizable lipid and the neutral phospholipid, and when the molar ratio of the cationic lipid to the ionizable lipid is in a specific range, the lipid nanoparticle has higher biological activity, tumor targeting property and good safety.

The invention discloses a cholesterol modified double-stranded DNA membrane skeleton liposome delivery system and a preparation method and application thereof, and belongs to the technical field of drug delivery. The system is composed of cholesterol, distearoyl phosphatidylcholine, distearoyl phosphatidyl ethanolamine modified by methoxy polyethylene glycol and double-stranded DNA (chol-dsDNA) modified by 5 '-cholesterol, and the chol-dsDNA is anchored on the inner side and the outer side of a liposome membrane through a hydrophobic effect to form a bionic skeleton. The system is excellent in mechanical stability, low in drug leakage rate, high in tumor targeted enrichment capacity and good in biocompatibility, can efficiently entrap irinotecan hydrochloride and other hydrophilic drugs, is used for tumor treatment, and is simple and convenient to prepare and easy to scale.

Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

Provided herein are novel docking peptides and antibody-based drug conjugates that include such docking peptides. In embodiments, the subject docking peptide allows for the controlled attachment of one or more drug moieties and a tumor targeting moiety that allows for the targeting of the drug moiety to the tumor microenvironment.In some embodiments, the antibody-based drug conjugates provided herein advantageously allows for enhanced targeted delivery of a drug payload having a controlled drug-to-antibody ratio (DAR) to a target site.

This invention provides a chimeric antigen receptor (CAR) targeting both BCMA and GPRC5D antigens and its uses. The chimeric antigen receptor (CAR) includes an extracellular localization signaling domain, an antigen domain targeting BCMA, an antigen domain targeting GPRC5D, a hinge region, a transmembrane region, a co-stimulatory factor, and an intracellular CD3ξ signaling domain. The antigen domain targeting BCMA includes a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 1 and a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 2. The antigen domain targeting GPRC5D includes a light chain variable region with an amino acid sequence as shown in SEQ ID NO: 3 and a heavy chain variable region with an amino acid sequence as shown in SEQ ID NO: 4. The dual chimeric antigen receptor, including an antigen domain targeting BCMA and an antigen domain targeting GPRC5D, can simultaneously recognize two anti-tumor targets, preventing tumor immune escape.

This application provides a method for screening inhibitors targeting CYP7A1 and their use in the preparation of anti-liver cancer drugs, relating to the field of tumor targeted drug design technology. The method for screening inhibitors targeting CYP7A1 protein includes: using the crystal structure of human cholesterol 7α-hydroxylase as a receptor model, precise docking screening is performed using software to screen drug-like molecules with molecular weights of 250-500 Da and lipid-water partition coefficients of -1 to 5 from a compound database; a graph neural network active learning model is used to predict and rank the protein-small molecule binding affinity of compounds in the database; the ΔG between candidate molecules and CYP7A1 is calculated using molecular mechanics / generalized Born surface area methods, with molecules having ΔG ≤ -40 kcal / mol considered potential inhibitors. The inhibitors of this application do not rely on the enzymatic activity of CYP7A1 to achieve anti-tumor effects and do not significantly affect cholesterol and bile acid metabolism levels.

The application discloses a kind of intraoperative tumor rapid classification system based on hyperspectral technology, comprising: image pre-processing module, for the hyperspectral image of several frequency bands of acquired tumor lesion tissue is pre-processed;Tumor lesion area identification module is used to select the hyperspectral image corresponding to multiple preferred frequencies respectively, fusion obtains fusion spectrum image, tumor target detection is carried out based on the image, and tumor lesion area is identified;Tumor lesion type identification module is used to carry out multi-pixel sampling to the tumor lesion area identified, obtains the frequency characteristics of each preferred frequency of each sampling point, and respectively input benign and malignant tumor identification model, respectively output benign and malignant possibility matrix, to identify tumor lesion type.The present application discriminates tumor benign and malignant based on tumor lesion tissue hyperspectral image, realizes the rapid classification of intraoperative tumor lesion type, reduces the rapid identification time, improves the accuracy of identification result while improving the identification efficiency.

The invention discloses a real-time positioning method for a tumor target region and a gold label implant, and belongs to the technical field of tumor localization, and the method specifically comprises the following steps: implanting a gold label in a tumor region, constructing a gold label-tumor dynamic model through CT, and obtaining a respiratory phase feature vector; realizing space matching of the two-dimensional projection and the three-dimensional model by using an improved hybrid registration algorithm, and obtaining a tumor compound displacement vector; establishing a respiration-displacement correlation model through time sequence alignment, generating a tumor movement map containing a real-time position and a predicted trajectory, and updating the reference coordinate system; establishing a rigid safety boundary based on a gold label, analyzing soft tissue texture and a prediction trajectory in combination with a convolutional neural network to generate an elastic treatment boundary, and dynamically adjusting a dose weight of a non-label area; and finally, submillimeter-level dynamic tracking is executed through a multi-leaf collimator. The problems of tumor motion uncertainty and individual deformation difference are solved, and the target area coverage precision and the dose distribution reasonability are improved.

The invention relates to the field of biological medicine, in particular to application of NPEPL1-targeted small molecule compounds in preparation of tumor targeted therapy drugs, and four small molecule compounds, namely C301-9181, E859-1332, L281-0443 and C679-2629, which have a hepatocellular carcinoma cell killing effect and high NPEPL1 affinity are obtained for the first time. The small molecule compound realizes tumor targeted therapy by targeting NPEPL1 protein in tumor cells, and can be used for developing tumor targeted therapy drugs. According to the present invention, the potential treatment effect of the targeted intervention NPEPL1 on hepatocellular carcinoma and other malignant solid tumors with high NPEPL1 expression is provided, the optimal small molecule compound C301-9181 is obtained through layer-by-layer screening, the small molecule compound can be used for preparing the NPEPL1-targeting anti-tumor targeting drugs, the drug research and development blank in the NPEPL1 targeting treatment field is filled, and the broad application prospect is provided.

The invention provides an application of 2-indolecarboxylic acid in preparation of a tumor targeted therapy drug. Through computer-aided drug design and molecular docking optimization, 2-indolecarboxylic acid shows high binding energy to an HER2 kinase structural domain. In HER2 positive NCI-N87 gastric cancer cells, the 2-indolecarboxylic acid significantly inhibits cell proliferation and induces G0 / G1 phase arrest and apoptosis. The mechanism research shows that the 2-indoleformic acid can play a role by regulating and controlling the HER2 / Akt / beta-catenin pathway (Western blot verification). In an NCI-N87 cell tumor-bearing nude mouse model, 2-indolecarboxylic acid (15 mg / kg) significantly inhibits tumor growth, and does not cause obvious weight loss or organ toxicity. Immunohistochemical analysis shows that the positive rate of a tumor tissue proliferation marker Ki-67 in a treatment group is remarkably reduced, and apoptosis detection shows that the proportion of TUNEL positive cells is remarkably increased, which indicates that 2-indolecarboxylic acid inhibits tumor cell proliferation and promotes apoptosis at the same time. The invention provides a lead compound with clinical transformation potential for HER2 targeted therapy.

This invention relates to a method for precise localization of breast tumors based on multi-level double-layer coding, comprising the following steps: acquisition of scattered microwave signals; signal processing and feature construction; multi-level data label coding based on a breast model containing the tumor target: each level contains double-layer coding, the first layer of coding is coarse-grained localization, and the second layer of coding is fine-grained localization; the localization interval of the initial level is determined based on the breast model containing the tumor target; given the constraints of the termination coding, the localization interval of the next level is determined based on the current level's localization interval after data label double-layer coding; model training and coding prediction output.

The invention discloses a nano aggregate as well as a preparation method and anti-breast cancer application thereof. The nano aggregate comprises a drug-drug conjugate AI (formed by dehydration condensation of ATRA and IRI), an anoxic response type prodrug PAC (formed by coupling of CPUL119 and PEG through an azobenzene connecting bond), and a targeting molecule DT (DSPE-PEG2000-Try), wherein the drug-drug conjugate AI is formed by dehydration condensation of ATRA and IRI; the anoxic response type prodrug PAC is formed by coupling of CPUL119 and PEG through an azobenzene connecting bond; the preparation method comprises the following steps: respectively dissolving AI, PAC and DT in an organic solvent, dropwise adding an AI solution into deionized water, stirring for the first time, adding a PAC solution and a DT solution, and stirring again to obtain the nano aggregate. The nano aggregate disclosed by the invention has a uniform particle size of 90-130 nm and a high drug loading capacity (greater than 80%), stably exists in a physiological environment, and shows excellent tumor targeted accumulation capacity; the medicine is released through hypoxia / pH / esterase triple response, chemotherapy (IRI), differentiation therapy (ATRA) and ferroptosis therapy (CPUL119) are coordinated, and the killing effect on breast cancer cells and stem cells is remarkably enhanced.

This invention discloses a method for esophageal cancer tumor target region segmentation based on cross-modal feature fusion of PET / CT images. The method uses a Transformer-fused Attention Progressive Semantic Nested Network (TransAttPSNN) as the 3D segmentation model for esophageal cancer tumor target regions. The TransAttPSNN network has an AttPSNN backbone structure and includes two segmentation networks: one for PET streams and the other for CT streams. Transformer cross-modal adaptive feature fusion modules are embedded in the different feature levels of the two segmentation networks. Compared with existing technologies, this invention effectively improves the segmentation accuracy of esophageal cancer tumor target regions and achieves better segmentation performance.

This invention discloses an enzyme-responsive KRAS-targeting protein degradation chimera, its preparation method, and its application, belonging to the field of tumor targeted therapy technology. The enzyme-responsive KRAS-targeting protein degradation chimera of this invention is obtained by covalently linking three parts: a KRAS-targeting protein degradation chimera, an enzyme-responsive amino acid sequence, and a cell-penetrating peptide amino acid sequence. The KRAS-targeting protein degradation chimera is obtained by linking a KRAS-targeting peptide with a VHL E3 ligase ligase via succinic acid. The enzyme-responsive KRAS-targeting protein degradation chimera releases the KRAS-targeting protein degradation chimera upon cleavage by the ATG4 enzyme, exhibiting strong anti-lung cancer activity both in vitro and in vivo. This invention has significant advantages in anti-tumor drugs, opening up a new field for the development of targeted protein degradation chimera drugs. The molecular structure of the enzyme-responsive KRAS-targeting protein degradation chimera is as follows:

The invention relates to a cell membrane bionic drug-loaded carbon dot nano-material as well as a preparation method and application thereof. The nano-composite is prepared by the following steps: preparing carbon dots, cross-linking to form a reduction responsive carbon dot nano-cluster, sequentially loading chemotherapeutic drugs and coating a cancer cell membrane to form a nano-vaccine. After the nano vaccine is injected into the body of a mouse through caudal vein, the enrichment of the nano vaccine in a tumor part can be enhanced by utilizing the active tumor targeting characteristic of a cancer cell membrane, and tumor cells can be induced to generate immunogenic death through carried chemotherapy drugs and photothermal therapy, so that chemotherapy / photothermal / immune combined therapy on tumors is realized; the obvious anti-tumor effect is realized. In addition, as a nano vaccine, after subcutaneous injection, the nano vaccine can also utilize the tumor antigen carried by a cancer cell membrane and the adjuvant characteristics of the carbon dots to activate the anti-tumor immunity of an organism so as to prevent tumors, and has potential clinical application value.

The invention provides an anti-tumor targeting nano material and a preparation method thereof, and belongs to the field of novel targeting nano drugs. The method comprises the following steps: stirring and mixing up-conversion nanoparticles, calcium peroxide nanoparticles, manganese chloride and a chemotherapeutic drug in a water phase to obtain a drug-loading core; cystamine and 3-aminophenylboronic acid are dissolved in water, EDC and NHS are added, a first amidation reaction is carried out, and a cross-linking agent is obtained; dispersing the drug-loading core in a polyacrylic acid solution, adding a cross-linking agent, and then carrying out a cross-linking reaction to obtain an intermediate product; activating carboxyl on the surface of the intermediate product, and then carrying out second amidation reaction with cRGD-PEG-NH2, so as to obtain the anti-tumor targeting nano material. According to the application, a multifunctional nano platform integrating targeted enrichment, double-response precise drug release, chemotherapy-chemical kinetics-immune collaborative treatment and up-conversion imaging tracing is constructed, and specific efficient killing of tumors and inhibition of metastasis and relapse of the tumors are realized.

The invention discloses a thiophenol-heptamethine cyanine dye derivative as well as self-assembled nanoparticles, a preparation method and application thereof. The derivative is a thiophenol-heptamethine cyanine dye monomer derivative or a 1, 3, 5-benzene trithiophenol-heptamethine cyanine dye triad derivative; the thiophenol or the 1, 3, 5-benzene trithiophenol is connected with a meso-carbon atom of the heptamethine cyanine dye through a sulfur atom, and the heptamethine cyanine dye is formed by connecting two nitrogen-containing heterocyclic ring units through a conjugated methine chain; the nanoparticles are obtained by dropwise adding a derivative solution into water and then removing an organic solvent. The synthesis method of the thiophenol-cyanine dye derivative is simple and easy to implement, stable nanoparticles can be formed, the tumor targeting property can be improved, the aggregation effect far better than that driven by traditional weak interaction is achieved, synchronous optimization of high tumor accumulation and extremely high heat production efficiency is successfully achieved through self-assembly of nanoparticles, and the thiophenol-cyanine dye derivative has good application prospects. An innovative strategy is provided for the development of a high-performance tumor photo-thermal reagent.